Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Digital PCR Platform Harnesses Microfluidic Technology for Quantification of Genetic Targets

By LabMedica International staff writers
Posted on 03 Apr 2023

Digital PCR (dPCR) is a powerful method that enables the precise and ultra-sensitive measurement of nucleic acids. More...

This technique offers enhanced accuracy and sensitivity for detecting low-level abundance nucleic acids in the case of bacterial and viral pathogens, resulting in absolute quantification and remarkable specificity. Although qPCR has been the go-to technique for pathogen detection, dPCR provides superior accuracy in the presence of inhibitors and does not require a standard curve for absolute quantification. Now, an easy-to-use dPCR platform harnesses cutting-edge microfluidic technology to integrate the dPCR workflow onto a single consumable chip, resulting in higher sensitivity and accuracy when detecting low-level abundance nucleic acids in the detection of bacterial and viral pathogens.

The naica system from Stilla Technologies (Villejuif, France) harnesses the key principles of digital PCR and is designed to provide a sensitive, fast, and easy-to-use platform for the quantification of genetic targets. It boasts the highest multiplexing capacity currently offered in the market for the simultaneous detection and quantification of multiple genetic targets in a single run. The naica system is based on Stilla’s Crystal Digital PCR technology that partitions samples into a large array of thousands of individual droplet crystals – each its own reaction compartment – before amplifying nucleic acid molecules in each droplet crystal. These reactions are tagged with fluorophores to be read using up to six different fluorescence light channels. This results in a fast and simple workflow that delivers high multiplexing capability with exceptional sensitivity while reducing time-to-results and conserving valuable samples.

The naica system simplifies any digital PCR application by combining high multiplexing assay design compatibility and powerful imaging with the flexibility to use up to six detection channels and proprietary software for analysis. Crystal Miner, the naica system’s proprietary software, offers intuitive visuals for image analysis, enabling thorough exploration of Droplet Crystals for quality control. Crystal Miner measures the concentrations of targeted nucleic acids, enabling automatic identification of positive and negative droplets for all fluorescence channels. The naica system requires minimal technical expertise, as it comes with optimized digital PCR reagents that are ready to use, simple pipetting steps, and chip consumables that are ready for partitioning, amplification, and read-out. Assays can be run with just a few minutes of actual hands-on time, making the naica system highly efficient and user-friendly.

Related Links:
Stilla Technologies 


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.